This tool is designed to assist clinicians in evaluating some of the key patient considerations for implantable cardioverter defibrillators (ICD) and cardiac resynchronization therapy defibrillators (CRT-D), by providing relevant landmark clinical trial overviews, Boston Scientific Indications for Use (labeling), applicable ACC/AHA/HRS Guidelines overviews, and CMS coverage policy summaries. This tool is currently limited to primary SCA prevention patient populations.
Select "Individual Patient" below if you have information pertaining to a specific patient's clinical considerations; or select "Trial Population" if you would like to explore information for a full trial population.
Boston Scientific does not promote the use of its products outside their FDA-approved label. The information provided in this tool references the most commonly referenced ICD and CRT-D patient considerations and is not intended to provide an all-inclusive list.
Health economic and reimbursement information provided by Boston Scientific Corporation is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice. Boston Scientific encourages providers to submit accurate and appropriate claims for services. It is always the provider's responsibility to determine medical necessity, the proper site for delivery of any services and to submit appropriate codes, charges, and modifiers for services that are rendered. Boston Scientific recommends that you consult with your payers, reimbursement specialists and/or legal counsel regarding coding, coverage and reimbursement matters. Payer policies will vary and should be verified prior to treatment for limitations on diagnosis, coding or site of service requirements.